Important note: Information in this article was accurate in July 2003. The state of the art June have changed since the publication date. |
AIDSWEEKLY Plus; Monday, July 28, 2003
Michael Greer, Senior Medical Writer
Punnee Pitisuttithum and colleagues at Mahidol University in Bangkok and other institutions in Thailand and the United States assessed the "safety and immunogenicity of two recombinant human immunodeficiency virus (HIV) type 1 envelope glycoprotein (gp) 120 vaccines derived from SF2 (subtype B) and CM235 (CRF01_AE, Thai E)".
Vaccine recipients demonstrated robust cellular and humoral activity against HIV gp120, Pitisuttithum and coauthors said.
In their study, a group of 370 Thai adults were immunized with CM235 or SF2 gp120 at a variety of doses or a placebo. All of the vaccine recipients developed binding antibody responses, and more than 80% of vaccine recipients demonstrated neutralizing antibodies against subtype B or E HIV strains, according to the report.
In addition, lymphoproliferative responses were seen in more than 95% of the immunized volunteers, study data showed. The response to SF2 - but not CM235 - gp120 was dose-dependent.
No severe adverse effects were linked to vaccination (Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis. 2003 Jul 15;188(2):219-27.
"The gp120 Thai E and SF2 vaccines were safe and immunogenic in combination and could be advanced into phase 3 testing," Pitisuttithum and colleagues concluded.
The corresponding author for this report is Punnee Pitisuttithum, Vaccine Trial Centre, Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok 10400, Thailand. E-mail: tmppt@mucc.mahidol.ac.th.
Key points reported in this study include:
A pair of novel HIV gp120-based vaccines are safe and effective in healthy Thai adults
The two vaccines use gp120 from subtype B (SF2) and subtype E (CM235) strains
Most recipients showed both cellular and neutralizing antibody responses
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
Pitisuttithum P, Nitayaphan S, Thongcharoen P, et al., "Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults", J Infect Dis. 2003 Jul 15;188(2):219-27.
PubMED Related articles Search
030728
AW030711
Copyright © 2003 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.